meta
|
evidence
COVID-19
Living systematic review and meta-analysis
azithromycin plus hydroxychloroquine
***** adjuvant therapies
***** anti-inflammatoty and immuno-therapy
***** antiandrogenic
antiviral and associated therapy
hydroxychloroquine plus macrolides
azithromycin plus hydroxychloroquine
***** control
***** Drugs for acid related disorders
***** miscellaneous
***** Oral antidiabetic drugs
***** Renin-angiotensin-system-acting agents
***** vaccines
***** Vitamins
COVID-19 mild to moderate
COVID 19 hospitalized
COVID 19 all comers
COVID-19 mild to moderate
COVID-19 severe or critically
COVID 19 outpatients
COVID-19 (hospitalized or not)
COVID-19 prophylaxis (children)
COVID-19 prophylaxis (excluding children)
infections other than COVID-19
Long COVID-19
preventing respiratory virus transmission
secondary prevention
Meta-analysis results for all treatments
Treatment relative effect with 95% CI; and degree of certainty (adaptated from GRADE).
method
Treament
Trials
Summary
Endpoints
deaths
deaths (time to event analysis only)
clinical deterioration
clinical improvement
clinical improvement (14-day)
hospitalization
mechanical ventilation
viral clearance
viral clearance by day 7
ICU admission
serious adverse events
acute kidney injury
adverse events
arrhythmia
elevated liver enzymes
long QT
Thromboembolic events
deaths, clinical deterioration, clinical improvement, viral clearance
deaths
deaths (time to event analysis only)
clinical deterioration
clinical improvement
clinical improvement (14-day)
hospitalization
mechanical ventilation
viral clearance
viral clearance by day 7
ICU admission
serious adverse events
acute kidney injury
adverse events
arrhythmia
elevated liver enzymes
long QT
Thromboembolic events
core analysis (OBS if no RCT)
RCTs only
all (RCT+OBS)
core analysis (OBS if no RCT)
core analysis (OBS if no RCT)
RCTs only
all (RCT+OBS)
clinical deterioration
clinical improvement
deaths
viral clearance